F
Frances B. Alvarez
Researcher at Merck & Co.
Publications - 5
Citations - 2646
Frances B. Alvarez is an academic researcher from Merck & Co.. The author has contributed to research in topics: Vaccination & Cervical intraepithelial neoplasia. The author has an hindex of 5, co-authored 5 publications receiving 2605 citations.
Papers
More filters
Journal ArticleDOI
A controlled trial of a human papillomavirus type 16 vaccine.
Laura A. Koutsky,Kevin A. Ault,Cosette M. Wheeler,Darron R. Brown,Eliav Barr,Frances B. Alvarez,Lisa M. Chiacchierini,Kathrin U. Jansen +7 more
TL;DR: Administration of this HPV- 16 vaccine reduced the incidence of both HPV-16 infection and HPV-15-related cervical intraepithelial neoplasia, and immunizing HPV-14-negative women may eventually reduce the probability of cervical cancer.
Journal ArticleDOI
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.
Constance Mao,Laura A. Koutsky,Kevin A. Ault,Cosette M. Wheeler,Darron R. Brown,Dorothy J. Wiley,Frances B. Alvarez,Oliver Bautista,Kathrin U. Jansen,Eliav Barr +9 more
TL;DR: The vaccine HPV16 L1 VLP provides high-level protection against persistent HPV16 infection and HPV16-related CIN2–3 for at least 3.5 years after immunization, likely to reduce risk for cervical cancer.
Journal ArticleDOI
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.
Keith S. Reisinger,Stan L. Block,Eduardo Lazcano-Ponce,Rudiwilai Samakoses,Mark T. Esser,Joanne Erick,Derek Puchalski,Katherine E.D. Giacoletti,Heather L. Sings,Suzanne Lukac,Frances B. Alvarez,Eliav Barr +11 more
TL;DR: In 9- to 15-year-old adolescents, the quadrivalent vaccine was generally well tolerated and induced persistent anti-HPV serologic responses in the majority of subjects for at least 12 months following completion of a three-dose regimen.
Journal ArticleDOI
Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
Daniel M. Musher,Susan B. Manoff,Charlie Liss,Richard D. McFetridge,Rocio D. Marchese,Bonnie Bushnell,Frances B. Alvarez,Carla Painter,Michael D. Blum,Jeffrey L. Silber +9 more
TL;DR: Both primary vaccination and revaccination with PN23 induce antibody responses that persist during 5 years of observation, and baseline geometric mean concentrations of IgG were higher in revaccinations than primary vaccination subjects.
Journal ArticleDOI
Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia
Constance Mao,Laura A. Koutsky,Kevin A. Ault,Cosette M. Wheeler,Darron R. Brown,Dorothy J. Wiley,Frances B. Alvarez,Oliver Bautista,Kathrin U. Jansen,Eliav Barr +9 more
TL;DR: There were no diagnoses of persistent HPV-16 infection among women who received all 3 doses of vaccine and completed 48 months of follow up (100% effective) and the level of anti-HPV-16 titers rose after each dose of vaccine.